yohimbine is the isolated active alkaloid
Liu YN, Qin Y, Wu B, Peng H, Li M, Luo H, Liu LL
Disposition : Structure: Acylated peptide with a fatty diacid moiety extends half-life via albumin binding Half-life: ~6 days supports once-weekly dosing Administration: Subcutaneous injection Clinical Data Highlights : Weight Loss: Up to 24.2% body weight reduction in phase 2 trials, highest recorded among incretin-based therapies Glycemic Control: HbA1c reductions of 2.02.5% in type 2 diabetes patients Lipid Profile: Significant drops in triglycerides, LDL-C, and liver fat content Insulin Sensitivity: Improved HOMA-IR and fasting insulin levels Energy Expenditure: Increased basal metabolic rate and fat oxidation via glucagon receptor activation For a full breakdown of Retatrutide clinical trials and results you can click the link
Regan JA, Cao Y, Dispenza MC, Ma S, Gordon LI, Petrich AM, et al
Grficos de Avo Media A continuacin una aproximacin al contenido del audio de este video